Litchfield Caroline
SEC CIK 1854928 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co. | EVP, CFO | 94.2K | — | $11.50M | 19 | 2021-11-04 | 2026-04-29 |
Most active insiders at MRK, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Zachary Jennifer | EVP, GC | — | $25.20M |
| 2 | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | — | $11.29M |
| 3 | Guindo Chirfi | EVP, Access, Policy, Comms | — | $8.15M |
| 4 | Williams David Michael | EVP, Chief Info, Digital Off | — | $8.13M |
| 5 | Davis Robert M | COB, CEO, Pres, Dir | — | $5.60M |
| 6 | Litchfield Caroline | EVP, CFO | — | $5.02M |
| 7 | Li Dean Y | Pres, Executive VP, MRL | — | $2.99M |
| 8 | Maraldo David R. | EVP, Pres. MMD | — | $2.41M |
| 9 | Oosthuizen Johannes Jacobus | Pres, U.S. Market | — | $1.83M |
| 10 | Smart Dalton E. III | SVP Fin. - Gbl Ctrl | — | $766.0K |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-01 17:39 | 2026-04-29 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $110.03 | +3,935 | 94.2K | +4% | +$433.0K |
| D | 2026-05-01 17:39 | 2026-04-29 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | F - Tax | $110.03 | -1,938 | 92.3K | -2% | -$213.2K |
| D | 2026-02-06 | 2026-02-04 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | S - Sale+OE | $119.61 | -42.0K | 90.2K | -32% | -$5.02M |
| D | 2026-02-06 | 2026-02-04 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $53.06 | +42.0K | 132.2K | +47% | +$2.23M |
| 2026-01-28 | 2026-01-26 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | A - Grant | $107.40 | +15.9K | 90.2K | +21% | +$1.70M | |
| 2025-01-29 | 2025-01-27 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | A - Grant | $97.94 | +23.4K | 74.3K | +46% | +$2.29M | |
| D | 2024-02-15 | 2024-02-14 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $58.08 | +38.3K | 89.2K | +75% | +$2.22M |
| D | 2024-02-15 | 2024-02-14 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | S - Sale+OE | $125.50 | -38.3K | 50.9K | -43% | -$4.81M |
| 2024-01-24 | 2024-01-22 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | A - Grant | $119.43 | +19.2K | 50.9K | +61% | +$2.29M | |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $115.47 | +866 | 32.1K | +3% | +$100.0K |
| D | 2023-05-03 | 2023-05-01 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | F - Tax | $115.47 | -427 | 31.7K | -1% | -$49.3K |
| 2023-01-25 | 2023-01-23 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | A - Grant | $109.88 | +2,656 | 30.2K | +10% | +$291.8K | |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $87.65 | +773 | 27.8K | +3% | +$67.8K |
| D | 2022-05-04 | 2022-05-03 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | F - Tax | $87.65 | -373 | 27.4K | -1% | -$32.7K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | F - Tax | $88.69 | -427 | 27.0K | -2% | -$37.9K |
| D | 2022-05-03 | 2022-05-01 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $88.69 | +866 | 27.5K | +3% | +$76.8K |
| 2022-02-28 | 2022-02-24 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | A - Grant | $73.51 | +2,429 | 26.6K | +10% | +$178.6K | |
| D | 2021-11-05 | 2021-11-04 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | M - OptEx | $0.00 | +22.7K | 42.4K | +115% | $0 |
| D | 2021-11-05 | 2021-11-04 | MRK | Merck & Co. | Litchfield Caroline | EVP, CFO | S - Sale+OE | $91.00 | -18.3K | 24.1K | -43% | -$1.67M |
Purchase Sale Sale after option exercise All abbreviations